Used to treat the symptoms of prostate cancer, Triptorelin Acetate CAS# 149194-24-7 is a man-made form of a hormone that regulates many functions in the body. Triptorelin is effectual at over stimulating the body’s own production of these specific hormones, therefore causing the production of these hormones to shut down. This shut down is triggered temporarily, and the patient begins to experience elevated testosterone levels. These reactions, which are elicited by the administration of triptorelin, are essential for the palliative treatment of advanced prostate cancer. Known as Trelstar, which is marketed by Watson, the patent for triptorelin is set to expire on July 7, 2015.
As the second leading cause of cancer death among American men, prostate cancer is also the most common form of cancer found in American males. Over 2 million men in the United States currently have prostate cancer, and that number is sure to rise with the aging population. Triptorelin is a gonadotropin-releasing hormone (GnRH) agonist, and it is administered subcutaneously. Doses are offered as subcutaneous injections, typically given every 4, 12, or 24 weeks.
A recent study published in The Scientific World Journal examined the use of triptorelin as a treatment for central precocious puberty. Using a dosage of 11.25 milligrams, researchers studied a small group of females who were experiencing central precocious puberty, also known as CPP. Children with CPP typically have the development of gonadotropin dependent onset of puberty before the age of 8 years in girls and 9 years in boys. Conclusions from this study were encouraging, showing that quarterly triptorelin dosages of 11.25 mg is effective in suppressing pituitary-gonadal axis during the first year of treatment. This unique off-label usage for triptorelin is intriguing for research and development teams worldwide.
LGM Pharma provides the triptorelin acetate API for R&D purposes, and offers clients complete support throughout the development process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.